168 related articles for article (PubMed ID: 30851448)
1. Effect of vaccination against oral HPV-16 infection in high school students in the city of Cali, Colombia.
Castillo A; Osorio JC; Fernández A; Méndez F; Alarcón L; Arturo G; Herrero R; Bravo LE
Papillomavirus Res; 2019 Jun; 7():112-117. PubMed ID: 30851448
[TBL] [Abstract][Full Text] [Related]
2. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
Combita AL; Reyes V; Puerto D; Murillo R; Sánchez R; Nuñez M; Hernandez-Suarez GA; Wiesner C
Cancer Prev Res (Phila); 2022 Jan; 15(1):55-66. PubMed ID: 34610993
[TBL] [Abstract][Full Text] [Related]
3. Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States.
Chaturvedi AK; Graubard BI; Broutian T; Pickard RKL; Tong ZY; Xiao W; Kahle L; Gillison ML
J Clin Oncol; 2018 Jan; 36(3):262-267. PubMed ID: 29182497
[TBL] [Abstract][Full Text] [Related]
4. Human Papillomavirus (HPV) Vaccine Effectiveness and Potential Herd Immunity for Reducing Oncogenic Oropharyngeal HPV-16 Prevalence in the United Kingdom: A Cross-sectional Study.
Mehanna H; Bryant TS; Babrah J; Louie K; Bryant JL; Spruce RJ; Batis N; Olaleye O; Jones J; Struijk L; Molijn A; Vorsters A; Rosillon D; Taylor S; D'Souza G
Clin Infect Dis; 2019 Sep; 69(8):1296-1302. PubMed ID: 30590469
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Oral Human Papillomavirus Infection by Number of Vaccine Doses Among US Adults.
Abel MK; Mann AK; Sonawane K; Kapp DS; Deshmukh AA; Chan JK
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34993415
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of oral human papillomavirus infection among university students in Valencia, Spain.
Sastre-Cantón M; Pérez-Vilar S; Vilata-Corell JJ; Díez-Domingo J
Vaccine; 2019 Oct; 37(43):6276-6281. PubMed ID: 31515148
[TBL] [Abstract][Full Text] [Related]
7. Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men-United States, 2016-2018.
Meites E; Winer RL; Newcomb ME; Gorbach PM; Querec TD; Rudd J; Collins T; Lin J; Moore J; Remble T; Swanson F; Franz J; Bolan RK; Golden MR; Mustanski B; Crosby RA; Unger ER; Markowitz LE
J Infect Dis; 2020 Nov; 222(12):2052-2060. PubMed ID: 32504091
[TBL] [Abstract][Full Text] [Related]
8. Rates and determinants of oral human papillomavirus infection in young men.
Edelstein ZR; Schwartz SM; Hawes S; Hughes JP; Feng Q; Stern ME; O'Reilly S; Lee SK; Fu Xi L; Koutsky LA
Sex Transm Dis; 2012 Nov; 39(11):860-7. PubMed ID: 23064535
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus vaccine uptake, knowledge and attitude among 10th grade students in Berlin, Germany, 2010.
Stöcker P; Dehnert M; Schuster M; Wichmann O; Deleré Y
Hum Vaccin Immunother; 2013 Jan; 9(1):74-82. PubMed ID: 22995838
[TBL] [Abstract][Full Text] [Related]
11. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway.
Enerly E; Flingtorp R; Christiansen IK; Campbell S; Hansen M; Myklebust TÅ; Weiderpass E; Nygård M
PLoS One; 2019; 14(10):e0223612. PubMed ID: 31600341
[TBL] [Abstract][Full Text] [Related]
12. Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway.
Feiring B; Laake I; Christiansen IK; Hansen M; Stålcrantz J; Ambur OH; Magnus P; Jonassen CM; Trogstad L
J Infect Dis; 2018 Nov; 218(12):1900-1910. PubMed ID: 30010913
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial.
Lehtinen M; Apter D; Baussano I; Eriksson T; Natunen K; Paavonen J; Vänskä S; Bi D; David MP; Datta S; Struyf F; Jenkins D; Pukkala E; Garnett G; Dubin G
Vaccine; 2015 Mar; 33(10):1284-90. PubMed ID: 25593103
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial.
Lehtinen M; Apter D; Eriksson T; Harjula K; Hokkanen M; Lehtinen T; Natunen K; Damaso S; Soila M; Bi D; Struyf F
Int J Cancer; 2020 Jul; 147(1):170-174. PubMed ID: 31736068
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of oral HPV infection in the United States, 2009-2010.
Gillison ML; Broutian T; Pickard RK; Tong ZY; Xiao W; Kahle L; Graubard BI; Chaturvedi AK
JAMA; 2012 Feb; 307(7):693-703. PubMed ID: 22282321
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination.
Mollers M; Scherpenisse M; van der Klis FR; King AJ; van Rossum TG; van Logchem EM; Feltkamp MC; Meijer CJ; Snijders PJ; Boot HJ; de Melker HE
Cancer Epidemiol; 2012 Dec; 36(6):519-24. PubMed ID: 22906483
[TBL] [Abstract][Full Text] [Related]
17. Risk perception and sexual behavior in HPV-vaccinated and unvaccinated young Colombian women.
Ruiz-Sternberg AM; Pinzón-Rondón ÁM
Int J Gynaecol Obstet; 2014 Sep; 126(3):205-8. PubMed ID: 24996685
[TBL] [Abstract][Full Text] [Related]
18. Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine.
Schlecht NF; Masika M; Diaz A; Nucci-Sack A; Salandy A; Pickering S; Strickler HD; Shankar V; Burk RD
JAMA Netw Open; 2019 Oct; 2(10):e1914031. PubMed ID: 31651968
[TBL] [Abstract][Full Text] [Related]
19. Facilitators and barriers HPV unvaccinated girls after 5 years of program implementation.
Firenze A; Marsala MG; Bonanno V; Maranto M; Ferrara C; Giovannelli L; Restivo V
Hum Vaccin Immunother; 2015; 11(1):240-4. PubMed ID: 25483543
[TBL] [Abstract][Full Text] [Related]
20. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
